Tag: regulatory affairs

Vendor and Partner Oversight Models That Reflect ICH E6(R3) Proportionality Vendor and Partner Oversight Models That Reflect ICH E6(R3) Proportionality The increasing complexity of clinical trials demands innovative approaches to vendor and partner oversight. As outlined in the ICH E6(R3) guidelines, these models must reflect a principle of proportionality, ensuring that oversight is commensurate with…

Read More “Vendor and Partner Oversight Models That Reflect ICH E6(R3) Proportionality” »

ICH E6(R3) and Patient-Centricity: Rebalancing Burden and Benefit ICH E6(R3) and Patient-Centricity: Rebalancing Burden and Benefit The paradigm of clinical research has evolved significantly, particularly in the context of the increasing emphasis on patient-centric approaches. As global regulatory bodies such as the FDA, EMA, and MHRA advocate for integrating patient voices in clinical trials, adherence…

Read More “ICH E6(R3) and Patient-Centricity: Rebalancing Burden and Benefit” »

Inspection Readiness in the Era of ICH E6(R3): New Expectations for Evidence Inspection Readiness in the Era of ICH E6(R3): New Expectations for Evidence Introduction to Inspection Readiness and ICH E6(R3) The evolving landscape of clinical trials necessitates a framework that enhances compliance and ensures data integrity. The International Council for Harmonisation (ICH) E6(R3) guidelines…

Read More “Inspection Readiness in the Era of ICH E6(R3): New Expectations for Evidence” »

Cross-Functional RACI Models for Implementing ICH E6(R3) Across the Portfolio Cross-Functional RACI Models for Implementing ICH E6(R3) Across the Portfolio The successful implementation of ICH E6(R3) guidelines requires a comprehensive understanding of roles, responsibilities, and compliance expectations across different functional areas within pharmaceutical and clinical research organizations. In this article, we will provide a step-by-step…

Read More “Cross-Functional RACI Models for Implementing ICH E6(R3) Across the Portfolio” »

Risk Assessment and Risk Control Requirements Under Updated GCP Understanding Risk Assessment and Risk Control Requirements Under Updated GCP Introduction to ICH E6(R3) and Its Impact on Clinical Trials The International Council for Harmonisation (ICH) has been instrumental in setting the standards for Good Clinical Practice (GCP) globally. The release of ICH E6(R3) introduces significant…

Read More “Risk Assessment and Risk Control Requirements Under Updated GCP” »

Proportionate GCP Oversight for Low-Intervention and Pragmatic Clinical Trials Clinical trials serve as the cornerstone of medical research, enabling the testing of new treatments and medical interventions to improve patient outcomes. However, the extent of oversight and regulation applied to clinical trials can vary significantly based on the nature of the trial itself. This article…

Read More “Proportionate GCP Oversight for Low-Intervention and Pragmatic Clinical Trials” »

Embedding ICH E6(R3) Into SOPs, Templates and Study Governance The International Council for Harmonisation (ICH) E6(R3) provides comprehensive guidance intended to strengthen the quality of clinical trials globally. This article outlines a structured approach for clinical operations, regulatory affairs, and medical affairs professionals to effectively embed ICH E6(R3) principles into Standard Operating Procedures (SOPs), templates,…

Read More “Embedding ICH E6(R3) Into SOPs, Templates and Study Governance” »

From E6(R2) to E6(R3): Translating New GCP Principles Into Site and Sponsor Practice From E6(R2) to E6(R3): Translating New GCP Principles Into Site and Sponsor Practice The ongoing evolution of Good Clinical Practice (GCP) directly influences the operation and management of clinical trials in regulated environments such as the US, UK, and EU. With the…

Read More “From E6(R2) to E6(R3): Translating New GCP Principles Into Site and Sponsor Practice” »

Designing Quality by Design Frameworks That Align With ICH E6(R3) The International Conference on Harmonisation (ICH) E6(R3) is a paradigm shift in clinical trial design and conduct that emphasizes the principles of Quality by Design (QbD). This framework aims to enhance the quality of clinical trials, particularly focusing on the integration of proportionality principles. This…

Read More “Designing Quality by Design Frameworks That Align With ICH E6(R3)” »

ICH E6(R3) GCP Principles: What Clinical and Regulatory Teams Must Change Now ICH E6(R3) GCP Principles: What Clinical and Regulatory Teams Must Change Now The introduction of the ICH E6(R3) guidelines represents a significant shift in Good Clinical Practice (GCP) principles, orienting clinical operations towards a more risk-based and patient-centric approach. As clinical trial teams…

Read More “ICH E6(R3) GCP Principles: What Clinical and Regulatory Teams Must Change Now” »